Allerayde SAB Inc

Allerayde SAB Inc

November 14, 2013 18:00 ET

Allerayde SAB to attend major Industry Event: CPhI Worldwide 2013

LONDON, UNITED KINGDOM--(Marketwired - Nov. 14, 2013) - Allerayde SAB (OTCQB:ASAB) today announced that the company has participated in a leading Pharmaceutical Industry marketing and networking event, CPhI Worldwide 2013, with a goal of identifying potential new development and distribution partners.

This was a first for Allerayde SAB but after careful research it was decided that the company would get the opportunity to network with some leading partners and academics.

CPhI Worldwide is the world's leading pharmaceutical networking event with over 29,000 attendees from 133 countries and 2,200 exhibitors. Giving Allerayde SAB the opportunity to meet face-to-face with international pharmaceutical companies and, stay informed about the latest industry trends and remain one step ahead of a constantly changing pharmaceutical market.

Mr. Michael Rhodes (CEO) comments "This was a great opportunity for Allerayde SAB to meet key people in our industry and most importantly look at adding new assets to our development and research schedule. 2013 has far exceeded our expectations, with new partners coming on and hopefully new researchers and partner products to launch in the near future. Allerayde and the team are working tirelessly to design and deliver leading edge products that keep us in the forefront of our market".

About Allerayde SAB, Inc.:

Allerayde SAB, Inc. is engaged in the business of developing and manufacturing an innovative anaphylaxis pen product and other consumer health care products for allergy and eczema patients.

The Company's principal product is the AAAPen®. The AAAPen® is a new epinephrine/adrenaline pen for the emergency treatment of anaphylaxis, the severe allergic shock, which may be identified by various rapid onset symptoms following exposure to certain allergens-such as insect venoms, peanuts, seafood, latex, etc.- that have caused symptoms from different level reactions. When the first signs of anaphylaxis being experienced, the AAAPen® shall be used.

Allerayde is also engaged in developing and manufacturing products for the prevention and relief of allergy, asthma and eczema.

Allerayde SAB, Inc. trades on the Over the Counter Market with the ticker symbol ASAB. For more information about the company please visit our website at:

Forward Looking Statements:

This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward‐looking public statements concerning its expected future operations, performance and other developments. Such forward‐looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such.

Forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, the Company's ability to develop operations, the Company's ability to consummate and complete an acquisition, the Company's access to future capital, the successful integration of acquired companies, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, sales and other factors that may be identified from time to time in the Company's public announcements. This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

Contact Information